Back to top
more

Cancer Genetics, Inc. (CGIX)

(Delayed Data from NSDQ)

$0.22 USD

0.22
777,576

-0.01 (-3.17%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.23 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[CGIX]

Reports for Purchase

Showing records 1 - 20 ( 65 total )

Industry: Medical Services

Record: 1

04/28/2019

Company Report

Pages: 4

Termination of coverage due to resource reallocation

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 2

10/23/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CGIX

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Industry: Medical Services

Record: 3

09/21/2018

Company Report

Pages: 4

Oncomine Comprehensive Assay Next-Generation Version Introduced; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 4

09/19/2018

Company Report

Pages: 5

NovellusDx Merger Announced; Potentially Transformative Transaction; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 5

08/15/2018

Company Report

Pages: 4

2Q18 Financial Results Reported; Top-Line Miss, Net Loss In-Line; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 6

06/27/2018

Company Report

Pages: 4

Recent Developments in Precision Medicine Bode Well; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 7

05/29/2018

Company Report

Pages: 4

1Q 2018 Financial Results Reported; Revenue Growth Lagging; Reducing Price Target to $3

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 8

04/06/2018

Company Report

Pages: 5

Lowering to Neutral on Strategic Review

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 9

02/06/2018

Company Report

Pages: 4

Leadership Transition Announced; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 10

01/29/2018

Model

Pages: 1

MODEL Please note: This model may be included in a separate report on the company issued by the broker on the same day.

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 11

01/18/2018

Company Report

Pages: 4

Immuno-Oncology Panel Expansion Underscores Leadership; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 12

01/16/2018

Company Report

Pages: 4

Turning the Corner in 2018; Cash Replenished; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 13

11/29/2017

Company Report

Pages: 5

3Q17 Financial Results Reported; Looking Ahead to Profitability

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 14

09/29/2017

Company Report

Pages: 5

VivoPharm Acquisition, 25th I-O Contract - BUY

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 15

09/21/2017

Company Report

Pages: 5

Management Discussions Highlight Potential Future Strategic Directions; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 16

08/15/2017

Company Report

Pages: 4

2Q17 Financial Results Reported; Edging Towards Profitability; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 17

06/27/2017

Company Report

Pages: 23

We are initiating coverage with a BUY rating and 12-18 month price target of $11.00 per share

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 75.00

Research Provided by a Third Party

Industry: Medical Services

Record: 18

05/15/2017

Company Report

Pages: 4

1Q17 Financial Results Reported; Profitability Gradually Approaching; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 19

05/15/2017

Company Report

Pages: 4

1Q17 Financial Results Reported; Profitability Gradually Approaching; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical Services

Record: 20

05/05/2017

Company Report

Pages: 4

Complete::IO? Immuno-Oncology Assay Validation Achieved; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party